Marielle Rassi Khoury’s Post

Have you had a chance to read Suki Kandola's latest article on navigating the AMCP Format 5.0? Suki delves into the pivotal updates in the AMCP format, highlighting the importance of early engagement, pre-approval information exchange, the integration of real-world evidence, and addressing health disparities. These insights are critical for anyone striving to optimize market access and improve healthcare outcomes. At Envision Pharma Group, we recognize that these strategic elements are crucial in ensuring our innovations reach the patients who need them most. Suki and her team are at the forefront of driving impactful changes in this vital area.

Navigating the AMCP Format for Formulary Submissions has evolved with Version 5.0, transforming our approach to value and access strategies. No longer just a standardised process, these updates promote a more strategic and collaborative approach, focusing on early engagement, real-world evidence, and addressing health disparities.   In this article, I explore: - The healthcare landscape's shift towards value-based care - Key updates in AMCP Format 5.0, including smarter early engagement, the power of real-world evidence (RWE), and the importance of addressing health disparities - Practical strategies for navigating these changes to ensure your product's successful launch and improved patient access   Read my analysis of these transformative changes in my latest article with Envision Pharma Group: https://lnkd.in/didyz4-A

Streamline your AMCP process

We're excited to share an insightful deep dive by Suki Kandola, Global Head of Value & Access, on the latest updates in the AMCP Format for Formulary Submissions Version 5.0., covering value-based care, early engagement strategies, and the importance of real-world evidence and health disparities. This piece highlights practical strategies for navigating these changes, ensuring successful product launches and better patient access. Advancing with these new insights is crucial for staying ahead in the healthcare landscape, accelerating formulary submissions, and improving patient outcomes. https://lnkd.in/gRgn_35a   #Healthcare #Pharma #ValueBasedCare #PatientAccess #RealWorldEvidence #EnvisionPharma

Medical and economic value and access to patients are the factors that can sink or swim a therapy’s market launch. As regulatory agencies prioritize value-based care, early engagement strategies, and the importance of real-world evidence and health disparities, how are you preparing for future launches?  Our recent blog from Suki Kandola dives into updates in the AMCP Format for Formulary Submissions Version 5.0, providing practical strategies and best practices to ensure successful product launches.  

Excited to attend the ACF Advance Planning Briefing to Industry conference at NIH! Looking forward to gaining insights, networking, and exploring innovative opportunities in healthcare. #ACFConference #NIH #HealthcareInnovation"

With the rise of precision medicine, market access strategies in LATAM require a nuanced approach. Understanding local diversity and regulatory frameworks is key to aligning your biomedical innovation with health system needs and patient populations. It's not just about meeting regulatory requirements; it's about ensuring that your innovations reach the right patients effectively. With precision medicine, you can make a meaningful impact on patient outcomes and the success of your healthcare solutions. Leave it in our hands #ceibohealthconsulting #HEOR #LATAM

For those who could not join the Economic Forum in Karpacz in September, here is the summary and video of the Chiesi CEE (Chiesi Group) sponsored panel discussion on “Future-proofing Central and Eastern European Health Systems”: Video: https://lnkd.in/d_5KEMcq Article: https://lnkd.in/dD5WqeSi The panel discussion brought together experts from key countries in the region to address shared challenges and propose potential solutions. The theme took on particular significance in light of the dynamic changes underway in the healthcare sector in the region. The discussion brought together insights: - dorica dan, President, National Alliance for Rare Diseases, Romania, - Jakub Dvořáček , Deputy Minister, Ministry of Health, Czechia, - Marcin Czech, Professor, former Deputy Minister of Health, Poland, - Tomáš Doležal, Founder, iHETA, Czechia, - Bertalan Németh, Principal Health Economist, Syreon Research Institute, Hungary, as well as moderator - Tomasz Kluszczynski, Strategy Consultant and Founder, ACESO Healthcare Consulting, Poland. The key conclusions were: ✔ real innovation in healthcare lies in collaboration not only among different stakeholders within a given country but also on cross-border joint projects and initiatives. ✔ involving patients in decision-making processes is not only an ethical requirements but also a crucial practical solution for ensuring a more equitable and effective healthcare system. ❗ The ultimate take away from the panel is the need for further development of HTA systems with patient involvement, supporting international cooperation, and creating integrated care systems that provide better quality of life for patients, particularly those suffering from rare diseases. #EconomicForum #Karpacz2024 #Healthcare #ChiesiCEE #HTA #Innovations #PublicHealth #Patientadvocacy #Patientaccess #OMP's #RareDisease #DrugPolicy #PatientInclusion #Patientempowerment #MCDA #CEEhealtcaresystem

🎬 Discover how Brazil's healthcare system transformed with public engagement in health technology assessment. Watch the inspiring journey of Trastuzumab's inclusion in SUS, showcasing the impact of collective voices in shaping life-saving policies. Join us to see the power of community in healthcare! Contact us for assistance : Contact us for more info: bioxplore.org Check the reference : Carvalho VKDS, de Sousa MSA, Barreto JOM, da Silva EN. Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation. BMC Health Serv Res. 2019 Oct 28;19(1):762. doi: 10.1186/s12913-019-4555-6. PMID: 31660957; PMCID: PMC6819332. #BrazilianHealthcare #TrastuzumabSuccess #PublicHealth #HealthTechAssessment #CONITEC #PatientEngagement #BreastCancerTreatment #HealthcareInnovation #PublicConsultation #LifeSavingDecisions #HealthPolicy #CommunityImpact #SUSBrazil #MedicalAdvancements

For a holistic view of the health ecosystem in the southeast with a strong focus on collaboration impact...